/FSNUY

FSNUY Stock - Fresenius SE & Co. KGaA

Q: What is the analyst price target for FSNUY?

Analyst price target information is not currently available for FSNUY.

Q: What is FSNUY's market cap?

Market capitalization information is not currently available for FSNUY.

Healthcare|Medical - Care Facilities|OTC

$14.07+0.79%

+$0.11 (+0.79%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-33.9%upside

Target: $9.30

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for FSNUY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.92

52W High$33.93

52W Low$8.58

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$21.83B	$22.30B	$40.84B	$37.52B	$36.28B
Gross Profit	$5.38B	$5.06B	$10.72B	$10.31B	$10.32B
Gross Margin	24.6%	22.7%	26.3%	27.5%	28.4%
Operating Income	$1.78B	$1.14B	$3.51B	$4.16B	$4.38B
Net Income	$471.00M	$-594,000,000	$1.37B	$1.82B	$1.71B
Net Margin	2.2%	-2.7%	3.4%	4.8%	4.7%
EPS	$0.05	$-0.07	$0.61	$0.82	$0.77

Company Overview

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

63%

Hold / Neutral

38%

Sell / Underperform

Analyst Consensus🟡 Mixed

5 Bullish3 Neutral/Bearish

Price Targets

No price targets available

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 9th 2023	Deutsche Bank	Upgrade	Buy	-
August 1st 2023	Citigroup	Resumed	Buy	-
July 12th 2023	Goldman	Initiation	Neutral	-
December 12th 2022	Citigroup	Initiation	Buy	-
November 28th 2022	UBS	Upgrade	Buy	-
October 18th 2022	Morgan Stanley	Initiation	Equal Weight	-
August 12th 2022	HSBC Securities	Upgrade	Buy	-
May 10th 2022	HSBC Securities	Downgrade	Hold	-

Earnings History & Surprises

FSNUY

Beat Rate

75%

Last 16 quarters

Avg Surprise

-39.9%

EPS vs Estimate

Beats / Misses

12/4

Last 12 quarters

Latest EPS

$0.23

Q4 2025

EPS Surprise History

Q1 24

-698.5%

$-1.20vs$0.20

Q2 24

+5.9%

$0.20vs$0.19

Q3 24

+15.5%

$0.22vs$0.19

Q4 24

+7.5%

$0.19vs$0.18

Q1 25

-0.6%

$0.18vs$0.18

Q2 25

+9.9%

$0.23vs$0.21

Q3 25

+10.0%

$0.24vs$0.22

Q4 25

+10.6%

$0.23vs$0.21

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 25, 2026	—	—	—	—
Q4 2025	Nov 5, 2025	$0.21	$0.23	+10.6%	✓ BEAT
Q3 2025	Aug 6, 2025	$0.22	$0.24	+10.0%	✓ BEAT
Q2 2025	May 7, 2025	$0.21	$0.23	+9.9%	✓ BEAT
Q1 2025	Feb 26, 2025	$0.18	$0.18	-0.6%	✗ MISS
Q4 2024	Nov 6, 2024	$0.18	$0.19	+7.5%	✓ BEAT
Q3 2024	Jul 31, 2024	$0.19	$0.22	+15.5%	✓ BEAT
Q2 2024	May 8, 2024	$0.19	$0.20	+5.9%	✓ BEAT
Q1 2024	Mar 19, 2024	$0.20	$-1.20	-698.5%	✗ MISS
Q4 2023	Nov 2, 2023	$0.16	$0.17	+3.6%	✓ BEAT
Q3 2023	Aug 2, 2023	$0.17	$0.18	+2.9%	✓ BEAT
Q2 2023	May 9, 2023	$0.17	$0.19	+13.1%	✓ BEAT
Q1 2023	Feb 21, 2023	$0.23	$0.20	-14.7%	✗ MISS
Q4 2022	Oct 30, 2022	$0.17	$0.14	-16.7%	✗ MISS
Q3 2022	Aug 2, 2022	$0.21	$0.21	+0.2%	✓ BEAT
Q2 2022	May 4, 2022	$0.21	$0.23	+7.5%	✓ BEAT
Q1 2022	Feb 22, 2022	$0.26	$0.27	+5.3%	✓ BEAT
Q4 2021	Nov 2, 2021	—	$0.22	—	—
Q3 2021	Jul 30, 2021	—	$0.26	—	—
Q2 2021	May 6, 2021	—	$0.24	—	—

Frequently Asked Questions about FSNUY

What is FSNUY's current stock price?

Fresenius SE & Co. KGaA (FSNUY) is currently trading at $14.07 per share. The stock has moved +0.79% today.

What is the analyst price target for FSNUY?

The average analyst price target for FSNUY is $9.30, based on 1 analyst.

What sector is Fresenius SE & Co. KGaA in?

Fresenius SE & Co. KGaA operates in the Healthcare sector, specifically within the Medical - Care Facilities industry. The company is traded on the OTC exchange.

What is FSNUY's market cap?

Fresenius SE & Co. KGaA has a market capitalization of $126.80 billion, making it a large-cap company.

Does FSNUY pay dividends?

No, Fresenius SE & Co. KGaA does not currently pay a dividend to shareholders.